Jpmorgan Chase & CO Veracyte, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Veracyte, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 434,971 shares of VCYT stock, worth $14.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
434,971
Previous 346,587
25.5%
Holding current value
$14.6 Million
Previous $11.8 Million
46.04%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding VCYT
# of Institutions
337Shares Held
80.2MCall Options Held
212KPut Options Held
18.5K-
Vanguard Group Inc Valley Forge, PA8.21MShares$275 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.79MShares$261 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI6.6MShares$221 Million0.42% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.2MShares$141 Million1.46% of portfolio
-
Wellington Management Group LLP Boston, MA4.08MShares$137 Million0.03% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $2.39B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...